1. Vietnam Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
DHG Pharmaceutical Joint Stock Company

DHG Pharmaceutical Joint Stock Company

HHOSE:DHG
88,000.00
VND
-1,100.00
(-1.23%)
12.19TMarket Cap
Dec 02Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
25,937.13
29,927.92
27,626.5
43,477.96
31,073.62
29,692.12
29,803.98
28,724.53
30,617.85
35,764.1
38,354.53
37,361.49
40,283.91
- -
Basic EPS, GAAP
4,505.11
4,079.15
4,507.99
7,880.02
4,913.4
4,994.64
4,859.71
5,658.87
5,943.36
7,560.11
8,034.8
5,957.5
6,519.16
- -
Free Cash Flow per Basic Share
1,037.6
127.34
2,384.27
5,850.07
3,035.07
1,911.69
5,974.47
5,639.7
3,279.96
5,103.73
-1,882.56
9,398.97
9,039.13
- -
Dividend per Share
1,756.58
1,006.56
2,004.59
3,511.32
3,338.96
3,000
2,500
4,000
4,000
3,500
3,499.52
7,500
10,000
- -
Book Value per Share
15,155.87
17,415.84
19,176.88
21,687.94
21,013.43
23,975.69
25,791.54
27,258.72
28,963.6
32,823.45
37,117.25
31,318.38
31,643.51
26,146.7
Tangible Book Value per Share
13,809.71
16,038.84
17,210.68
19,684.34
19,164.12
22,174.34
24,181.91
25,651.91
27,389.71
31,279.91
35,726.31
29,956.15
30,309.48
24,823.34
Basic Weighted Avg Shares
131
131
131
87
131
131
131
131
131
131
131
131
131
133
Sales/Revenue/Turnover
3,390,797
3,912,518
3,607,760
3,783,045
4,062,753
3,882,128
3,896,754
3,755,619
4,003,164
4,676,016
5,015,395
4,884,868
5,266,963
- -
Operating Margin (%)
17.71
18.42
19.02
20.54
17.79
18.08
17.54
21.23
21.46
22.99
20.97
17.64
18.07
- -
Depreciation Expense
71,043
79,709
89,670
93,721
92,010
88,607
88,711
88,197
83,876
81,001
88,704
169,695
119,008
- -
Net Income, GAAP
588,960
533,273
588,701
685,645
642,408
653,029
635,388
739,875
777,071
988,455
1,050,663
778,920
852,354
- -
Effective Tax Rate (%)
24.09
26.06
15.49
8.99
10.69
11.03
11.49
10.05
10.14
10.11
9.36
13.88
13.61
- -
Profit Margin (%)
17.37
13.63
16.32
18.12
15.81
16.82
16.31
19.7
19.41
21.14
20.95
15.95
16.18
- -
Working Capital
1,202,317
1,266,561
1,441,741
1,728,114
1,674,248
2,146,149
2,429,025
2,664,367
2,963,183
3,407,236
3,452,951
2,813,711
2,922,819
2,230,261
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
1,999,443
2,293,625
2,521,236
2,869,783
2,759,094
3,144,262
3,377,551
3,568,039
3,790,010
4,291,537
4,852,935
4,094,755
4,137,265
3,418,579
Return on Invested Capital (%)
24.32
21.42
1.16
22.67
19.78
18.33
17.13
19.93
20.23
23.59
21.53
16.34
19.12
- -
Return on Capital (%)
30.47
23.34
22.5
23.07
20.59
19.63
17.96
20.31
20.29
23.79
21.85
15.64
19.55
- -
Return on Common Equity (%)
32.1
25.05
24.64
25.7
23.01
22.2
19.53
21.33
21.14
24.47
22.98
17.41
20.71
- -

Capital Structure

VND

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
32,561
32,561
32,561
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
131
131
131
Market Capitalization
13,375,323
13,192,279
12,185,534

Working Capital

VND

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
3,888,768
3,991,624
3,744,553
Cash, Cash Equivalents & STI
2,153,896
2,222,282
1,731,908
Accounts Receivable, Net
595,567
571,746
650,937
Inventories
1,024,619
1,121,181
1,236,196
Total Current Liabilities
965,950
731,251
1,514,292
Payables & Accruals
- -
- -
- -
ST Debt
32,561
32,561
32,561
Deferred Revenue
- -
- -
- -

Growth Rates

VND

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.49%
3.59%
1.04%
Free Cash Flow
-51.48%
-145.23%
-3.83%
Net Income, GAAP
4.76%
4.42%
9.43%
Sales/Revenue/Turnover
4.04%
7.18%
7.82%
Total Cash Common Dividend
- -
- -
33.33%

Quarterly Revenue

VND

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,258,519
1,105,832
1,061,839
1,458,678
4,884,868
2025
1,194,545
1,184,237
- -
1,742,472
5,266,963
2026
1,198,100
1,363,150
- -
- -
- -

Quarterly Earnings Per Share

VND

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,699.7
1,424
1,154
1,541
5,957.5
2025
2,036.31
1,758
- -
1,367
6,519.16
2026
2,414.43
2,216
- -
- -
- -

Quarterly Dividends Per Share

VND

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
3,384.83
- -
7,500
2025
4,000
5,821.61
- -
- -
10,000
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Toshiyuki Ishii
Full Time Employees
2,819
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Can Tho Vietnam
IPO Date
Dec 21, 2006
Website
dhgpharma.com.vn
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
DHG Pharmaceutical Joint Stock Company (DHG Pharma) is a Vietnam-based pharmaceutical manufacturing and distribution company engaged in the research, development, production, and commercialization of finished pharmaceutical formulations, consumer health products, and dietary supplements. Founded in 1974 and headquartered in Can Tho, Vietnam, the company operates as a subsidiary of Japan-based Taisho Pharmaceutical Co., Ltd. DHG Pharma operates across two core business segments: Pharmaceutical Products and Functional Foods & Health Supplements. Its systematic product portfolio comprises more than 300 active formulations spanning major therapeutic classes, including analgesics and antipyretics under the flagship Hapacol brand; systemic antibiotics and antimicrobials under brand names such as Klamentin, Haginat, and Zaromax; cardiovascular, metabolic, and antidiabetic treatments; gastrointestinal and hepatobiliary formulations, including the Naturenz liver support brand; respiratory, anti-allergy, and cough remedies; musculoskeletal and nervous system therapies; dermatological, wound care, and cosmetic preparations; ophthalmic and sensory organ solutions; and effervescent multivitamins, dietary supplements, and nutritional products marketed under the Bocalex line. The company manufactures products across a variety of dosage forms, such as film-coated tablets, effervescent tablets, hard and soft gelatin capsules, oral suspensions, dry powders, sachets, ointments, and topical creams. DHG Pharma serves domestic retail pharmacies, hospital networks, clinics, and medical institutions through an extensive nationwide distribution network of regional branches, while also exporting commercial medicines to international markets across Southeast Asia and other emerging territories. In recent developments, DHG Pharma completed and secured European Union Good Manufacturing Practice (EU-GMP) certification for its new Betalactam manufacturing facility in Tan Phu Thanh Industrial Zone, establishing dedicated cephalosporin and penicillin production lines to qualify for high-tier hospital tender channels (Group 1 and Group 2 bidding) and expand contract manufacturing; deepened technology transfer and operational integration with majority shareholder Taisho Pharmaceutical to co-develop advanced OTC and prescription formulations compliant with Japan-GMP and international standards; enhanced automated production capacities to accelerate export volume; and broadened its nutraceutical and preventive wellness portfolio to capture growing consumer demand for healthcare maintenance.